Xtalks Life Science Webinars, Online
2016-10-05
Oncology drug development is in a period of unprecedented innovation, driven by growth in the use of targeted therapies and immuno-oncology agents. Biomarkers that reflect the drug target or functional state of the immune system are key in the development process. As leaders in companion diagnostic development, Covance/LabCorp have supported more than 75 percent of FDA-approved companion diagnostics, including all the current examples of diagnostics used in the area of immuno-oncology. Biomarker approaches that drive the area of precision medicine include: - Cell-based assays involving flow cytometric evaluation of cell populations or the production of proinflammatory markers
- Tissue based biomarker assays, including immunohistochemistry
- Genomic biomarkers, such as mutational burden and gene expression patterns
This webinar, presented by Chief Scientific Officer at Covance, Steve Anderson, PhD, will address the spectrum of immunotherapy development considerations and their implications for drug developers. Please join us for an insightful discussion on these clinically and commercially relevant topics.
|
|